Skip to content

Pharmacokinetic Study of Danhong Injection in Healthy Human Subjects

Pharmacokinetic Study of Danhong Injection in Healthy Human Subjects

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-13003571
Enrollment
Unknown
Registered
2013-06-18
Start date
2013-09-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group A:Danhong injection, 4 ml, intramuscularly administered. Plasma and urinary drug concentration were monitored within 24 h after the intramuscular dosing,metabonomic fingerprint of serum and urin
Group B:Danhong injection, 20 ml, intravenously infused. Plasma and urinary drug concentration were monitored within 24 h after the intravenous dosing,metabonomic fingerprint of serum and urine and th
Group C:Danhong injection, 40 ml, intravenously infused. Plasma and urinary drug concentration were monitored within 24 h after the intravenous dosing,metabonomic fingerprint of serum and urine and th
Group D:Male subjects of Group B, Danhong injection, 20 ml once daily for 7 days, intravenously infused. Plasma and urinary drug concentration were monitored afterintravenous dosing,metabonomic finger

Sponsors

Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Second Affilitated Hospital of Tianjin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Healthy human subjects, evenly divided between male and female, should be between 18 to 35 years old, with age difference of the same batch of subjects less than 10 years old; 2. Subjects with body weight greater than 50 kg and body mass index (BMI) not exceeding the ideal value more than 15%; BMI= body weight in kg/(height in m)2 (the ideal value 19–24); 3. Subjects with normal result of physical examination,laboratory tests,and biochemical tests; 4. Subjects willing to impart the food and drugs ingested within one week; 5. Subjects signed Informed Consent Form prior to this study according to the GCP guidance.

Exclusion criteria

Exclusion criteria: 1. Subjects who had primary disease in key organs including heart, liver and kidneys, or had a history of gastrointestinal disease, metabolic disease or neurological disease; 2. Subjects who had mental or physical disability, or subjects with a history of lunacy; 3. Subjects with clinically significant abnormalities in physical examination, biochemistry, blood and urine analysis, electrocardiography, chest X-ray, or ultrasound screening; 4. Subjects with a history of drug dependence, drug abuse or alcoholism; 5. Subjects with physical allergy or known allergic to Danshen, Honghua, or Danshen or Honghua gradient and product; 6. Subjects who took any Danshen- or Honghua-related drug, food, health-care product, medicated diet within one week prior to this study; 7. Subjects who took any falavonol-enriched drinks, food, or drugs that contained apple, oion, tea, broccoli, cherry, strawberry, or ginkgo biloba before the study day; 8. Subjects who took any medication with known damaging effects on main organs within three months prior to this study, or took any over-the-counter or prescription drugs within two week prior to this study, or participated any other investigational drug study within four week prior to this study; 9. Subjects who had tendency of haemorrhage; 10. Menstrual, pregnant or breast-feeding women and women at childbearing age take oral contraceptive. 11. Subjects with abnormal vital signs (systolic blood pressure 140 mmHg, or diastolic blood pressure 90 mmHg, or heart rate 100 bpm); 12. Subjects who frequently took alcohol with six months (i.e., more than 14 Units of alcohol every week) or took more than one cigarette every day with three months prior to this study; 13. Subjects who took any soft drugs (e.g., marijuana) with three month or took any hard drugs (e.g., cocaine, phencyclidine, etc) with one year prior to this study; 14. Subjects with risk factors that possibly influence the absorption, disposition, excretion and metabolism. 15. Subjects who donate blood within three month prior to this study; 16. In the opinion of the investigator, subjects who are not suitable to participate in the study for whatever reasons must be excluded.

Design outcomes

Primary

MeasureTime frame
plasma concentration;urinary concentration;Physical examination;number and function of Endothelial Progenitor Cell;Metabolic fingerprint of serum and urine;umber and function of Endothelial Progenitor Cells;biochemical test;

Countries

China

Contacts

Public ContactChuan Li

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

chli@simm.ac.cn+86 21 50803106

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026